Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of a Cardiovascular Health Promotion Program in Youth - The Tyrolean Early Vascular Ageing-study (EVA-Tyrol)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03929692
Recruitment Status : Completed
First Posted : April 29, 2019
Last Update Posted : April 29, 2019
Sponsor:
Collaborators:
Tiroler Landeskrankenanstalten GmbH (TILAK)
Tiroler Gebietskrankenkasse (TGKK)
InfPro IT Solutions GmbH
Genossenschaft Milchhof Sterzing (Dairy Farm Sterzing)
Austrian Research Promotion Agency FFG (K Project)
Public Health Service of South Tyrol, Italy
Information provided by (Responsible Party):
Medical University Innsbruck

Brief Summary:
Atherosclerosis - the main cause of cardiovascular diseases - starts already in childhood. The Tyrolean Early Vascular Ageing-study aims to improve the vascular health of Tyrolean adolescents by a multi-layer intervention program.

Condition or disease Intervention/treatment Phase
Atherosclerosis Life Style Behavioral: Multi-layer health promotion program Other: Standard health education Not Applicable

Detailed Description:

Cardiovascular diseases (CVDs) are the leading non-communicable cause of death. Primary prevention measures aim to improve the awareness of the individual risk profile and promote healthy lifestyle. Multiple evaluations have shown, that atherosclerosis - the main cause of CVDs - begins already early in life. Therefore, prevention programs have to start already in childhood.

The EVA-Tyrol study is a prospective, biomedical cohort study. 2000 participants will be recruited from high schools and training companies spread over North- and East-Tyrol (Austria) and South-Tyrol (Italy). For the 1500 participants included in the intervention group two examinations will be scheduled within a two-year interval. Participants will be in the 10th grade (mean age, 15-16 years) at the baseline and in the 12th grade (mean age, 17-18 years) at the follow-up examination. 500 participants in the 12th grade without participation in a health promotion program will serve as a control group. The 2000 participants equal roughly 5% of the Tyrolean population of the included age-group. Medical examination includes an extensive questionnaire, anthropometric measurements, fasting blood sampling, high-resolution ultrasound of the common carotid artery, and carotid-femoral pulse wave velocity. Active intervention will consist of (1) enhancing knowledge about CVDs, (2) individual medical counseling based on the results of the baseline examination, (3) providing an online health promotion tool and (4) involvement of participants in planning and conduction of health promotion projects. Main outcome parameter is the difference in the number of ideal health metrics as defined by the American Heart Association between the intervention and control group.

This study aims to improve cardiovascular health in Tyrolean adolescents and to evaluate the efficacy of this multi-layer health promotion program. Moreover, the investigators expect numerous insights in the prevalence of vascular risk conditions and early vascular pathologies in adolescents.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2102 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The Intervention Group (mean age 15-16 years at the baseline and 17-18 years at follow-up) will be compared to a Control Group (mean age 17-18 years) that did not participate in the health promotion program.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Effect of a Cardiovascular Health Promotion Program in Youth - The Tyrolean Early Vascular Ageing-study
Actual Study Start Date : May 2015
Actual Primary Completion Date : February 2019
Actual Study Completion Date : February 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Atherosclerosis

Arm Intervention/treatment
Intervention Group
Intervention will consist of (1) enhancing knowledge about CVDs, (2) individual medical counseling based on the results of the baseline examination, (3) providing an online health promotion tool and (4) involvement of participants in planning and conduction of health promotion projects.
Behavioral: Multi-layer health promotion program
Other: Standard health education
Control Group
Adolescents of same age as intervention group at follow-up examination that did not participate in health promotion program.
Other: Standard health education



Primary Outcome Measures :
  1. Effect of health promotion. [ Time Frame: 2 years ]
    Difference in the number of AHA's seven health goals in the ideal range between the intervention and the control Group.


Secondary Outcome Measures :
  1. Change in vascular health. [ Time Frame: 2 years ]
    Difference (decrease, stagnation, increase) of the number of achieved number of AHA's seven health goals in the ideal range between the baseline and the follow-up examination of the intervention group.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   14 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Intervention group: Participants must be in 10th school grade or aged 15 to 16 years when recruited in training companies.
  • Control Group: Participants must be in 12th school grade or aged 17 to 18 years when recruited in training companies.

Exclusion Criteria:

- none


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03929692


Locations
Layout table for location information
Austria
Department of Pediatrics II (Neonatology), Medical University of Innsbruck
Innsbruck, Tyrol, Austria, 6020
Italy
Department of Pediatrics, Bruneck Hospital
Bruneck, South Tyrol, Italy, 39031
Sponsors and Collaborators
Medical University Innsbruck
Tiroler Landeskrankenanstalten GmbH (TILAK)
Tiroler Gebietskrankenkasse (TGKK)
InfPro IT Solutions GmbH
Genossenschaft Milchhof Sterzing (Dairy Farm Sterzing)
Austrian Research Promotion Agency FFG (K Project)
Public Health Service of South Tyrol, Italy
Investigators
Layout table for investigator information
Principal Investigator: Ursula Kiechl-Kohlendorfer, MD Medical University of Innsbruck
Principal Investigator: Michael Knoflach, MD Medical University of Innsbruck

Layout table for additonal information
Responsible Party: Medical University Innsbruck
ClinicalTrials.gov Identifier: NCT03929692     History of Changes
Other Study ID Numbers: EVA1
First Posted: April 29, 2019    Key Record Dates
Last Update Posted: April 29, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Anonymized data can be shared in academic cooperations. Request for data can be addressed to the principal investigators with an appropriate research question.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases